Syk
信号通路图
研究领域
- 抑制剂选择性比较
- 溶解性比较
| 目录号 | 产品目录 | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | 酒精 | ||
| S2194 | R406 | <1 mg/mL | 100 mg/mL | 0 mg/mL |
| S2206 | R788 (Fostamatinib) Disodium | <1 mg/mL | 6 mg/mL | <1 mg/mL |
| S1533 | R406 (free base) | <1 mg/mL | 21 mg/mL | <1 mg/mL |
| S8032 | PRT062607 (P505-15, BIIB057) HCl | 86 mg/mL | 86 mg/mL | <1 mg/mL |
| S2625 | Fostamatinib (R788) | <1 mg/mL | 116 mg/mL | <1 mg/mL |
| S3026 | Piceatannol | <1 mg/mL | 48 mg/mL | 48 mg/mL |
| S4921 | MNS (3,4-Methylenedioxy-β-nitrostyrene, MDBN) | <1 mg/mL | 39 mg/mL | <1 mg/mL |
| S7286 | RO9021 | <1 mg/mL | 5 mg/mL | 7 mg/mL |
| S8442 | TAK-659 | 4 mg/mL | <1 mg/mL | <1 mg/mL |
| S7738 | PRT-060318 2HCl | 75 mg/mL | 75 mg/mL | <1 mg/mL |
| S7523 | Entospletinib (GS-9973) | <1 mg/mL | 26 mg/mL | <1 mg/mL |
| S7006 | BAY-61-3606 | <1 mg/mL | 14 mg/mL | <1 mg/mL |
- Syk抑制剂（12）
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S2194 |
R406R406是一种有效的Syk抑制剂，无细胞试验中IC50为41 nM，对Syk抑制作用强，但是不抑制Lyn，对Flt3的作用比对Syk低5倍。Phase 1。 |
Platelets (3 x 108/mL) were preincubated with Y27632 (10 uM), R406 (1 uM), or a combination of Y27632 and R406 for 20 minutes followed by stimulation with oxLDL (50 ug/mL) for 15 seconds and lysis. Samples were then separated by SDS-PAGE and were immunoblotted for phospho-MLCSer19, followed by reprobing for β-tubulin. (Fi) Representative blots. (Fii) Densitometric analysis of 3 independent experiments. *P < .05. Data are presented as mean ± SEM. Experiments were carried out in the presence of apyrase (2 U/mL), indomethacin (10 uM), and EGTA (1 mM).
|
|
| S2206 |
R788 (Fostamatinib) DisodiumR788 (Fostamatinib) Disodium是活性代谢物R406的前体药物，是一种Syk抑制剂，无细胞试验中IC50为41 nM，强效抑制Syk但不抑制Lyn，对Flt3作用效果弱5倍。Phase 3。 |
BCWM.1 and MWCL-1 cells treated with either vehicle or fostamatinib at the indicated concentrations for two hours, then protein extracts were analyzed by Western blotting for the activation status of MEK, p44/42 MAPK, and Akt with phospho-specific antibodies.
|
|
| S1533 |
R406 (free base)R406 (free base)是一种有效的Syk抑制剂，无细胞试验中IC50为41 nM，强效抑制Syk而不能抑制Lyn，对Flt3作用效果低5倍。Phase 1。 |
(C) Z-138 and JEKO-1 cells were simultaneously exposed to sorafenib and R406 at the indicated doses, and cell viability was determined at 48 hours by annexin V/PI staining. Bars represent the mean ± SD of 3 independent experiments. CI value is indicated for each combination. (D) Primary MCL cells from 7 patients were simultaneously exposed to sorafenib and R406 at the indicated doses for 48 hours, and cell viability was determined as above. Bars represent the mean ± SEM of all the samples analyzed. CI value is indicated for each combination. |
|
| S8032 |
PRT062607 (P505-15, BIIB057) HClPRT062607 (P505-15, BIIB057) HCl是一种新型的，高度选择性Syk抑制剂，无细胞试验中IC50为1 nM，作用于Syk比作用于Fgr，Lyn，FAK，Pyk2和Zap70选择性高80倍以上。 |
Ptpn6fl/fl and Inpp5dfl/fl ALL cells carrying 4-OHT-inducible Cre (Cre) or an empty vector were pre-treated with PRT062607 (2.5 µmol/L) for 2 days. Deletion of Ptpn6 (i) or Inpp5d (j) was induced by addition of 4-OHT and relative changes of GFP1 cells were monitored by flow cytometry.
|
|
| S2625 |
Fostamatinib (R788)Fostamatinib (R788)是活性代谢产物R406的前体药物，是一种Syk抑制剂，IC50为41 nM，强效抑制Syk但不抑制Lyn，对Flt3作用效果低5倍。Phase 3。 |
B cells were stimulated by irradiated CD40L+ L cells. Forward scatter vs. BrdU incorporation analysis (day 5) in the gated CD19+ CLL cells (D). The distribution of cells with high FSC (blasts, right quadrants) and proliferation (BrdU+, upper quadrants) are shown.
|
|
| S3026 |
PiceatannolPiceatannol，是一种天然二苯乙烯，是选择性Syk抑制剂，比作用于Lyn选择性高10倍左右。 |
Influence of piceatannol and resveratrol on hydrogen peroxide production by human subcutaneous fat tissue. H202 release was monitored on a 30-min period without any added agent, except the chromogenic mixture (basal), or with NADPH oxidase inhibitor (apocynin 10 μM, shaded column), each stilbene at 1 mM, or MAO and SSAO inhibitors (pargyline plus semicarbazide at 1 mM: parg + semi, dotted column). Each column is the mean ± SEM of 16 homogenates from obese patients. Different from basal hydrogen peroxide production at: **P < 0.01.
|
|
| S4921 |
MNS (3,4-Methylenedioxy-β-nitrostyrene, MDBN)MNS (3,4-Methylenedioxy-β-nitrostyrene, MDBN)是一种酪氨酸激酶抑制剂，抑制Syk， Src和p97， IC50分别为2.5 μM， 29.3 μM和1.7 μM。 |
WT mouse primary macrophages were untreated as control (lane 1) or treated with 0.1μg/ml E. coli LPS (lane 5-8), 10μM E-64 (lane 2 and 6), 250μM PMSF (lane 3 and 7), or 20μM MNS (lane 4 and 8). The cells were continuously cultured for 16 hrs. Extracts from whole cells or nuclei were separately purified and subjected to WB analysis with antibody against pERK2, LITAF, or actin/tubulin as control.
|
|
| S7286 |
RO9021RO9021有效地抑制Syk激酶活性，IC50为5.6nM。它还能够抑制B细胞受体信号通路。 |
||
| S8442 |
TAK-659TAK-659是一种有效的、选择性的SYK抑制剂。IC50为3.2 nM。对其他激酶具有选择性，对FLT3也能有效抑制，IC50为4.6 nM。 |
||
| S7738 |
PRT-060318 2HClPRT-060318 2HCl是一种新型选择性Syk酪氨酸激酶抑制剂，IC50为4 nM。是一种肝素诱导性血小板减少症的治疗方法。 |
||
| S7523 |
Entospletinib (GS-9973)Entospletinib (GS-9973)是一种口服具有生物活性的，选择性Syk抑制剂，无细胞试验中IC50为7.7 nM。在细胞中，对Syk的选择性比对其他激酶（如Jak2, ckit, Flt3, Ret, KDR）高13-1000倍。 |
(B) SYK(pY352) and PLCγ2(pY759) in CVID patients' CD21low B cells untreated (filled circles), in the presence of Entospletinib (open circle), or after washout of the inhibitor (gray circles) (n = 5).
|
|
| S7006 |
BAY-61-3606BAY-61-3606是一种有效的、选择性的Syk激酶抑制剂，Ki为7.5 nM。 |
-HCl-Haematological-20170209.gif)
